Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 20:54:38 +0200Tue, 26 Mar 2024 14:31:00 +0100Human medicines European public assessment report (EPAR): Upstaza, eladocagene exuparvovec, Date of authorisation: 18/07/2022, Revision: 7, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/upstazaHuman medicines European public assessment report (EPAR): Upstaza, eladocagene exuparvovec, Date of authorisation: 18/07/2022, Revision: 7, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/upstazaTue, 26 Mar 2024 14:31:00 +0100Human medicineOpinion/decision on a Paediatric investigation plan (PIP): Upstaza, Eladocagene exuparvovec, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0075/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002435-pip01-18-m03Opinion/decision on a Paediatric investigation plan (PIP): Upstaza, Eladocagene exuparvovec, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0075/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002435-pip01-18-m03Thu, 07 Mar 2024 15:00:00 +0100Human medicineUpstaza : EPAR - All Authorised Presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/h-5352-aa_en.pdfUpstaza : EPAR - All Authorised Presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/h-5352-aa_en.pdfTue, 09 Aug 2022 10:58:00 +0200Human medicine